We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
+14.74%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$792M
AUM Growth
+$9.15M
Cap. Flow
-$28.5M
Cap. Flow %
-3.6%
Top 10 Hldgs %
65.85%
Holding
54
New
9
Increased
12
Reduced
17
Closed
8

Top Buys

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$65.8M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$10.6M
3
FOLD
Amicus Therapeutics
FOLD
+$8.72M
4
ASND icon
Ascendis Pharma A/S
ASND
+$7.66M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$5.13M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$30.3M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$28.3M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$17.1M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$14.1M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 99.43%
2 Miscellaneous 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$92.6M 11.69%
10,488,076
– –
KITE
2
DELISTED
Kite Pharma, Inc.
KITE
$83.6M 10.56%
+806,750
New +$65.8M
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$59.7M 7.54%
5,930,956
+1,083,379
+22% +$8.72M
TSRO
4
DELISTED
TESARO, Inc.
TSRO
$56M 7.07%
400,403
-11,420
-3% -$1.65M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$12.4B
$45.5M 5.74%
500,789
-89,211
-15% -$8.12M
MDCO
6
DELISTED
Medicines Co
MDCO
$42.2M 5.32%
1,109,100
-75,900
-6% -$3.38M
DERM
7
DELISTED
Dermira, Inc.
DERM
$38.6M 4.88%
1,325,000
+122,687
+10% +$3.73M
TLGT
8
DELISTED
Teligent, Inc
TLGT
$37.8M 4.77%
413,080
+33,929
+9% +$2.89M
ARRY
9
DELISTED
Array Biopharma Inc
ARRY
$34.9M 4.41%
4,175,376
+395,376
+10% +$3.23M
IOVA icon
10
Iovance Biotherapeutics
IOVA
$4.16B
$30.5M 3.85%
4,151,343
-400,000
-9% -$2.54M
ASND icon
11
Ascendis Pharma A/S
ASND
$15.2B
$27.5M 3.47%
990,924
+290,000
+41% +$7.66M
GBT
12
DELISTED
Global Blood Therapeutics, Inc.
GBT
$23.5M 2.97%
860,000
+45,000
+6% +$1.34M
PCRX icon
13
Pacira BioSciences
PCRX
$950M
$22.2M 2.81%
465,818
+55,818
+14% +$2.59M
ACAD icon
14
Acadia Pharmaceuticals
ACAD
$4.63B
$17.1M 2.16%
614,200
-1,015,800
-62% -$30.3M
AVEO
15
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$14.7M 1.86%
663,245
+269,442
+68% +$2.12M
VNDA icon
16
Vanda Pharmaceuticals
VNDA
$302M
$14.7M 1.86%
902,146
+284,946
+46% +$4.11M
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
$13.2M 1.66%
140,700
-213,200
-60% -$13M
ASMB icon
18
Assembly Biosciences
ASMB
$551M
$12.5M 1.58%
50,597
-7,437
-13% -$2.09M
AGEN
19
Agenus
AGEN
$314M
$12.4M 1.57%
162,216
-9,426
-5% -$663K
AERI
20
DELISTED
Aerie Pharmaceuticals
AERI
$12.1M 1.53%
230,842
-194,158
-46% -$9.04M
BCRX icon
21
BioCryst Pharmaceuticals
BCRX
$2.07B
$10.9M 1.37%
1,953,525
+350,524
+22% +$2.14M
CPRX
22
DELISTED
Catalyst Pharmaceutical
CPRX
$10.5M 1.33%
3,804,745
– –
NBIX icon
23
Neurocrine Biosciences
NBIX
$15.3B
$10.1M 1.27%
+219,500
New +$10.6M
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.3M 1.05%
2,275,401
-107,800
-5% -$413K
ALIM
25
DELISTED
Alimera Sciences
ALIM
$8.19M 1.03%
392,772
+6,667
+2% +$143K
1
2 3

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Avoro Capital Advisors held 54 positions worth $792M, up 1.2% from $783M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Avoro Capital Advisors withdrew a net $28.5M in Q2 2017, closing 8 positions and reducing 17 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $28.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Avoro Capital Advisors opened a new position in Kite Pharma, Inc. worth $83.6M.

  • Avoro Capital Advisors's largest Q2 2017 buy was Kite Pharma, Inc.: 806,750 shares worth $83.6M.
  • Avoro Capital Advisors added most to Amicus Therapeutics in Q2 2017, an estimated $8.72M increase.
  • Avoro Capital Advisors's biggest Q2 2017 reduction was Acadia Pharmaceuticals, cutting an estimated $30.3M.
  • Avoro Capital Advisors fully exited Seagen Inc. Common Stock in Q2 2017, selling an estimated $28.3M.
  • Avoro Capital Advisors's ten largest holdings make up 66% of its $792M portfolio in Q2 2017.
  • Avoro Capital Advisors opened 9 new positions and closed 8 in Q2 2017.
  • Avoro Capital Advisors's portfolio value rose 1.2% quarter-over-quarter to $792M.

Based on Avoro Capital Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.